Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates
November 11, 2021 16:00 ET
|
Vyant Bio, Inc.
Strategic Highlights Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bio’s R&D programs targeting the identification of novel therapeuticsEntered into two new first...
Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference
November 10, 2021 16:15 ET
|
Vyant Bio, Inc.
Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Vyant Bio Announces Investor Conference Call and Webcast for the Third Quarter 2021
November 09, 2021 09:15 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Vyant Bio Announces Robert T. Fremeau, Jr. Ph.D. as Chief Scientific Officer
October 26, 2021 08:00 ET
|
Vyant Bio, Inc.
Cherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company identifying small and large molecule...
マソリ･セラピューティックスとビヤント･バイオ、新たな提携を発表
October 19, 2021 16:47 ET
|
Vyant Bio, Inc.
メリーランド州ベセスダ、東京、ニュージャージー州チェリーヒル発, Oct. 20, 2021 (GLOBE NEWSWIRE) -- 革新的な市場ソリューションの創出を通じて、競争上の優位性を達成するために人工知能を適用する、製薬業界に特化した企業であるマソリ･セラピューティックス (MASORI Therapeutics) と、中枢神経系 (「CNS」)...
MASORI THERAPEUTICS AND VYANT BIO, INC. ANNOUNCE NEW PARTNERSHIP
October 19, 2021 08:30 ET
|
Vyant Bio, Inc.
Engagement will combine MASORI’s global platforms and commercial experience in Japan to identify partnerships that leverage Vyant Bio’s advanced analytics and complex human-derived biology to drive...
MASORI THERAPEUTICS AND VYANT BIO, INC. ANNOUNCE NEW PARTNERSHIP
October 19, 2021 08:30 ET
|
Vyant Bio, Inc.
Engagement will combine MASORI’s global platforms and commercial experience in Japan to identify partnerships that leverage Vyant Bio’s advanced analytics and complex human-derived biology to drive...
Vyant Bio to Present at the H.C. Wainwright 23rd Annual Global Conference
September 09, 2021 08:00 ET
|
Vyant Bio, Inc.
Cherry Hill, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
August 19, 2021 09:27 ET
|
Vyant Bio, Inc.
CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cureCollaboration creates opportunities to identify, validate, and...
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
August 16, 2021 16:01 ET
|
Vyant Bio, Inc.
Strategic Highlights Received an issued US Patent titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States...